

# Effects of anaesthesia and oxytocin on maternal vascular tone

<b>Submission date</b> 14/03/2018	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 16/05/2018	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
<b>Last Edited</b> 23/11/2020	<b>Condition category</b> Pregnancy and Childbirth	<input type="checkbox"/> Individual participant data

## Plain English summary of protocol

### Background and study aims

Oxytocin is a drug routinely used in women to induce contraction of the uterus and prevent bleeding after childbirth. However it has side effects on the blood pressure and the heart which in some patients could lead to serious events.

This study aims to further investigate the effects of oxytocin on the human heart and blood vessels.

### Who can participate?

Women aged 18 and over scheduled for termination of pregnancy in first trimester

### What does the study involve?

Participants are randomly assigned to one of two groups. Those in the first group receive Oxytocin injections either early or late during the medical abortion, whilst under general anaesthetic. Those in the second group receive a placebo (dummy) injection either early or late during the medical abortion, whilst under general anaesthetic.

Participants are monitored using a pain-free device that analyses the pulse wave (change in blood volume as the heart contracts) in the finger, and a system that monitors blood pressure, heart rate and heart activity during the anaesthetic.

### What are the possible benefits and risks of participating?

Participants may benefit from further knowledge about the cardiovascular effects of oxytocin in a clinical setting. The study protocol does not differ from standard clinical procedure, except randomization and further non-invasive, non-painful monitoring.

### Where is the study run from?

Skåne University Hospital (Sweden)

### When is the study starting and how long is it expected to run for?

August 2012 – January 2017

### Who is funding the study?

1. Lund University (Sweden)
2. Region Skåne (Sweden)

Who is the main contact?  
Professor Per Olofsson (Scientific)  
per.olofsson@med.lu.se

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Prof Per Olofsson

**ORCID ID**  
<http://orcid.org/0000-0001-7840-525X>

**Contact details**  
Lund University  
Box 117  
Lund  
Sweden  
22100

## Additional identifiers

**EudraCT/CTIS number**

**IRAS number**

**ClinicalTrials.gov number**

**Secondary identifying numbers**  
1

## Study information

**Scientific Title**  
Effects of oxytocin and anaesthesia on vascular tone in pregnant women: a randomised double-blind placebo-controlled study using non-invasive pulse wave analysis

**Study objectives**  
Oxytocin decreases vascular tone and elevates cardiac output in first trimester pregnancy

**Ethics approval required**  
Old ethics approval format

**Ethics approval(s)**  
Regional Research Ethics Committee in Lund, 13/12/2012, ref: 2012/649

**Study design**

Randomised double-blind placebo-controlled single centre study

### **Primary study design**

Interventional

### **Secondary study design**

Randomised controlled trial

### **Study setting(s)**

Hospital

### **Study type(s)**

Diagnostic

### **Participant information sheet**

See additional file (in Swedish)

### **Health condition(s) or problem(s) studied**

Vascular tone and hemodynamic change in pregnancy

### **Interventions**

Participants are randomised by a web-based random number generator to a treatment or placebo group. Those in the treatment group receive 8.3 µg (5 U) Oxytocin by injection during the first trimester surgical evacuation of the gravid uterus under general anaesthesia. Those in the control group receive a placebo injection. The injections are administered once either early or late in the procedure, in a double-blind fashion.

The effects of oxytocin on the heart and the vascular tree are assessed using digital photoplethysmography pulse wave analysis (DPA) variables. The Meridian DPA (TM) works through an infra-red light emitting diode and receiver, measuring light absorption through the finger. The pulse wave through the finger augments the light absorption, and computer analysis generates a pulse volume curve. From the analysis of the waveform of this curve, hemodynamic estimates are computed and presented as 17 different variables. Some of these are shown to have the best repeatability, these are used in this study.

Also, heart rate, mean arterial blood pressure and electrocardiographic ST index are recorded. These variables are noted before and after induction of anaesthesia and 1 minute after each injection. No further follow up. DPA variables together with the other variables make it possible to assess the LV ejection function and vascular tone, possibly differentiating between that of large or small arteries.

### **Intervention Type**

Drug

### **Drug/device/biological/vaccine name(s)**

Oxytocin, Propofol

### **Primary outcome measure**

The effect of oxytocin on vascular tone and cardiac LV ejection fraction is assessed using digital photoplethysmography pulse wave analysis (DPA) variables before and 1 minute after each injection.

### **Secondary outcome measures**

The effect of anaesthesia on vascular tone and cardiac LV ejection fraction is assessed by digital photoplethysmography pulse wave analysis (DPA) variables before and after induction of anaesthesia.

**Overall study start date**

01/08/2012

**Completion date**

01/01/2017

## **Eligibility**

**Key inclusion criteria**

1. Women
2. Aged 18 years and over
3. Scheduled for termination of pregnancy in the first trimester by vacuum aspiration or curettage

**Participant type(s)**

Patient

**Age group**

Adult

**Lower age limit**

18 Years

**Sex**

Female

**Target number of participants**

51

**Total final enrolment**

51

**Key exclusion criteria**

1. Gestational age above 12 weeks in viable pregnancies
2. Age less than 18 years
3. Do not understand Swedish
4. Serious cardiovascular disorders.

**Date of first enrolment**

01/01/2013

**Date of final enrolment**

01/06/2013

## **Locations**

**Countries of recruitment**

Sweden

**Study participating centre**

Skåne University Hospital

Malmö

Sweden

20502

## **Sponsor information**

**Organisation**

Lund University

**Sponsor details**

Box 117

Lund

Sweden

22100

+46 46 222 0000

lu@lu.se

**Sponsor type**

University/education

**Website**

<https://www.lu.se/>

**Organisation**

Skåne University Hospital

**Sponsor details**

Diarium

Rådhus Skåne

Kristianstad

Sweden

29189

+46 40 331 000

region@skane.se

**Sponsor type**

Hospital/treatment centre

# Funder(s)

## Funder type

Government

## Funder Name

Lunds Universitet

## Alternative Name(s)

Lund University, Universitas Lundensis, Universitas Gothorum Carolina, Royal Caroline Academy, Regia Academia Carolina, Lund University | Lund, Sweden | LU, Lunds universitet, LU

## Funding Body Type

Government organisation

## Funding Body Subtype

Universities (academic only)

## Location

Sweden

## Funder Name

Region Skåne

# Results and Publications

## Publication and dissemination plan

Planned publication in a high-impact peer reviewed journal.

## Intention to publish date

01/06/2018

## Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study are/will be available upon request from Dr Sofus Rabow (sofus.rabow@med.lu.se)

## IPD sharing plan summary

Available on request

## Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Participant information sheet</a>		26/03/2018	01/04/2019	No	Yes
<a href="#">Participant information sheet</a>		26/03/2018	01/04/2019	No	Yes
<a href="#">Results article</a>	results	22/11/2018	23/11/2020	Yes	No

